153 related articles for article (PubMed ID: 38551811)
1. Unraveling MCL biology to understand resistance and identify vulnerabilities.
Sarkozy C; Tessoulin B; Chiron D
Blood; 2024 Mar; ():. PubMed ID: 38551811
[TBL] [Abstract][Full Text] [Related]
2. Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.
Saleh K; Cheminant M; Chiron D; Burroni B; Ribrag V; Sarkozy C
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804999
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.
Decombis S; Papin A; Bellanger C; Sortais C; Dousset C; Le Bris Y; Riveron T; Blandin S; Hulin P; Tessoulin B; Rouel M; Le Gouill S; Moreau-Aubry A; Pellat-Deceunynck C; Chiron D
Haematologica; 2022 Dec; 107(12):2905-2917. PubMed ID: 35263985
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression.
Zeng W; Fu K; Quintanilla-Fend L; Lim M; Ondrejka S; Hsi ED
Am J Surg Pathol; 2012 Feb; 36(2):214-9. PubMed ID: 22251940
[TBL] [Abstract][Full Text] [Related]
6. SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?
Li S; Tang G; Jain P; Lin P; Xu J; Miranda RN; Cheng J; Yin CC; You MJ; Wang ML; Medeiros LJ
Mod Pathol; 2024 Feb; 37(2):100405. PubMed ID: 38104893
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in genomics and therapeutics in mantle cell lymphoma.
Lu T; Zhang J; McCracken JM; Young KH
Cancer Treat Rev; 2024 Jan; 122():102651. PubMed ID: 37976759
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
9. A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
Araujo-Ayala F; Dobaño-López C; Valero JG; Nadeu F; Gava F; Faria C; Norlund M; Morin R; Bernes-Lasserre P; Serrat N; Playa-Albinyana H; Giménez R; Campo E; Lagarde JM; López-Guillermo A; Gine E; Colomer D; Bezombes C; Pérez-Galán P
Leukemia; 2023 Jun; 37(6):1311-1323. PubMed ID: 37031299
[TBL] [Abstract][Full Text] [Related]
10. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.
Yatabe Y; Suzuki R; Tobinai K; Matsuno Y; Ichinohasama R; Okamoto M; Yamaguchi M; Tamaru J; Uike N; Hashimoto Y; Morishima Y; Suchi T; Seto M; Nakamura S
Blood; 2000 Apr; 95(7):2253-61. PubMed ID: 10733493
[TBL] [Abstract][Full Text] [Related]
11. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
Condoluci A; Rossi D; Zucca E; Cavalli F
Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
[TBL] [Abstract][Full Text] [Related]
12. Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
Kahl BS; Dreyling M; Gordon LI; Quintanilla-Martinez L; Sotomayor EM
Leuk Lymphoma; 2017 Jul; 58(7):1561-1569. PubMed ID: 28140709
[TBL] [Abstract][Full Text] [Related]
13. Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma.
Mastorci K; Muraro E; Pasini E; Furlan C; Sigalotti L; Cinco M; Dolcetti R; Fratta E
PLoS One; 2016; 11(4):e0153823. PubMed ID: 27123851
[TBL] [Abstract][Full Text] [Related]
14. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
Nabrinsky E; Danilov AV; Koller PB
Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
[TBL] [Abstract][Full Text] [Related]
15. Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas.
Thomázy VA; Luthra R; Uthman MO; Davies PJ; Medeiros LJ
J Mol Diagn; 2002 Nov; 4(4):201-8. PubMed ID: 12411587
[TBL] [Abstract][Full Text] [Related]
16. SOX11, a key oncogenic factor in mantle cell lymphoma.
Beekman R; Amador V; Campo E
Curr Opin Hematol; 2018 Jul; 25(4):299-306. PubMed ID: 29738333
[TBL] [Abstract][Full Text] [Related]
17. PIK-75 overcomes venetoclax resistance
Huang S; Liu Y; Chen Z; Wang M; Jiang VC
Am J Cancer Res; 2022; 12(3):1102-1115. PubMed ID: 35411248
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma.
Wasik AM; Priebe V; Lord M; Jeppsson-Ahlberg Å; Christensson B; Sander B
Leuk Lymphoma; 2015 May; 56(5):1425-31. PubMed ID: 25120048
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
Alinari L; Prince CJ; Edwards RB; Towns WH; Mani R; Lehman A; Zhang X; Jarjoura D; Pan L; Kinghorn AD; Grever MR; Baiocchi RA; Lucas DM
Clin Cancer Res; 2012 Sep; 18(17):4600-11. PubMed ID: 22791882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]